Physicians' Academy for Cardiovascular Education

Severe hypoglycemia associated with increased risk of CV events and mortality

Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience

Literature - Zinman B, Marso SP, Christiansen E, et al. - Diabetes Care 2018; published online ahead of print

Introduction and Methods

There is an association between hypoglycemia and an increased risk of CV events and mortality, although the evidence for a causal effect is limited [1-3]. In this post hoc analysis of the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial [4], the associations between hypoglycemia and CV outcomes and mortality were investigated in patients with type 2 diabetes (T2DM).

In the double-blind, randomized, placebo-controlled LEADER trial, the glucagon-like peptide 1 analog liraglutide significantly reduced CV events and mortality compared with placebo, in T2DM patients at high CV risk, who additionally received standard care, and were followed for 3.5-5 years.

The primary end point in LEADER was the time to first occurrence of a major adverse CV event (MACE), including CV death, non-fatal myocardial infarction, or non-fatal stroke. Hypoglycemia was a secondary self-reported safety endpoint, and severe hypoglycemia was defined according to the American Diabetes Association criteria [5].

Main results


In the LEADER trial, patients with severe hypoglycemia episodes had a higher risk of MACE, CV death, non-CV death, and all-cause death compared with patients without severe hypoglycemia, particularly in the first 7 days after the hypoglycemic episode. These associations were independent of treatment group.


Show references

Download the slide Find this article online at Diabetes Care

Click here to view the slide

Share this page with your colleagues and friends: